Background P53 is the most widely investigated molecular marker in bladder cancer. We
aimed to review comprehensively the evidence for use of changes in P53 to predict bladder …

Cancer of the bladder shows divergent clinical behaviour following diagnosis and it has
been proposed that two major groups of tumours exist that develop via different molecular …

This 2004 volume in the World Health Organization series on histologic and genetic typing
of human tumors covers tumors of the kidney, urinary system, prostate, testis and …

Purpose: Fibroblast growth factor receptor 3 (FGFR3) mutations were recently found at a
high frequency in well-differentiated urothelial cell carcinoma (UCC). We investigated the …

The International Consensus Panel on cytology and bladder tumor markers evaluated
markers that have the ability to predict tumor recurrence, progression, development of …

The chromosomal region 12q13-q15 is recurrently amplified in bladder cancer. Putative
target genes located in this region include MDM2, CDK4, and GLI. To evaluate the …

Bladder cancer is associated with high recurrence and mortality rates. These tumors show
vast heterogeneity reflected by diverse morphologic manifestations and various molecular …

This study was designed to define the potential clinical relevance of identifying alterations
affecting p53 pathway in bladder cancer and to test a new, low-cost, high-throughput, and …

Cancer‐testis (CT) genes encode proteins that are ideal targets for cancer immunotherapy
because of their restricted expression in normal tissues and frequent expression in cancers …

Nested variant of urothelial carcinoma is characterized by confluent small nests and abortive
tubules of mildly atypical neoplastic cells infiltrating the lamina propria and/or muscularis …